Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Finished Drug Prices
NA
1. Glyceroltriheptanoate
2. Glyceryl Triheptanoate
1. 620-67-7
2. Propane-1,2,3-triyl Triheptanoate
3. Trienanthoin
4. Trioenanthoin
5. Glyceryl Triheptanoate
6. Glycerol Triheptanoate
7. Triheptanoic Glyceride
8. Heptanoin, Tri-
9. Ux007
10. Dermofeel Tc 7
11. Dojolvi
12. Propane-1,2,3-triyl Trisheptanoate
13. 2,3-di(heptanoyloxy)propyl Heptanoate
14. Dub Thg
15. Heptanoic Acid, 1,2,3-propanetriyl Ester
16. Dermofeel Tc-7
17. Ux-007
18. Radiamuls 2375
19. Lanol 37 T
20. Triheptanoin [usan]
21. 2p6o7cfw5k
22. 3-02-00-00769 (beilstein Handbook Reference)
23. Heptanoic Acid, 1,1',1''-(1,2,3-propanetriyl) Ester
24. Triheptanoin (usan)
25. Triheptylin
26. 1,2,3-propanetriyl Triheptanoate
27. Glyceroltriheptanoate
28. Brn 1807724
29. Lanol 37t
30. Einecs 210-647-2
31. Unii-2p6o7cfw5k
32. Trienantin
33. Dojolvi (tn)
34. Glycerol Trienanthate
35. Glyceryl Trienanthate
36. Triheptanoin [mi]
37. Triheptanoin [inn]
38. Ec 210-647-2
39. Triheptanoin [inci]
40. Schembl525618
41. Triheptanoin [who-dd]
42. Glycerol Trienanthate, >=94%
43. Chembl4297585
44. Gtpl11431
45. Dtxsid40862306
46. Propane-1,2,3-triyltriheptanoate
47. Triheptanoin [orange Book]
48. Zinc4521897
49. Ind106011
50. Mfcd00042910
51. Ux 007
52. 1r,2s-(-)-norephedrinehydrochloride
53. Cs-w013852
54. Db11677
55. Hy-w013136
56. Ind 106011
57. Ind-106011
58. Ind106011; Ux007
59. Ls-15081
60. Ft-0757070
61. D11465
62. A868568
63. Q414576
64. W-109093
Molecular Weight | 428.6 g/mol |
---|---|
Molecular Formula | C24H44O6 |
XLogP3 | 7.3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 23 |
Exact Mass | 428.31378912 g/mol |
Monoisotopic Mass | 428.31378912 g/mol |
Topological Polar Surface Area | 78.9 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 421 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders (lc-FAODs).
FDA Label
Triheptanoin is a source of medium chain fatty acids for patients with lc-FAODs. It has a moderate duration of action and a wide therapeutic window. Patients should be counselled regarding the risk of feeding tube dysfunction and intestinal malabsorption due to pancreatic insufficiency.
A - Alimentary tract and metabolism
A16 - Other alimentary tract and metabolism products
A16A - Other alimentary tract and metabolism products
A16AX - Various alimentary tract and metabolism products
A16AX17 - Triheptanoin
Absorption
A single 0.3 g/kg dose of triheptanoin reaches a Cmax of 178.9 mol/L, with a Tmax 0.5 h, and an AUC of 336.5 mol\*h/L. A single 0.4 g/kg dose of triheptanoin reaches a Cmax of 259.1 mol/L, with a Tmax 0.8 h, and an AUC of 569.1 mol\*h/L.
Route of Elimination
Triheptanoin is minimally eliminated in the urine.
Clearance
A single dose of 0.3 g/kg results in a mean apparent clearance of 6.05 L/h/kg for heptanoate. A single dose of 0.4 g/kg results in a mean apparent clearance of 4.31 L/h/kg for heptanoate.
Triheptanoin is hydrolysed to heptanoate, which can be further metabolized to -hydroxypentanoate or -hydroxybutyrate.
Due to multiple peak concentrations of the heptanoate metabolite, the half life of triheptanoin could not be determined.
Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with lc-FAODs treated with triheptanoin experienced improvements in hypoglycemia, cardiomyopathy, and rhabdomyolysis.
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2024-03-13
Pay. Date : 2024-02-16
DMF Number : 39534
Submission : 2024-02-12
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-03-21
Pay. Date : 2024-01-25
DMF Number : 39430
Submission : 2024-02-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-04-16
Pay. Date : 2024-03-22
DMF Number : 39441
Submission : 2024-03-26
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-04-16
Pay. Date : 2024-03-15
DMF Number : 39415
Submission : 2024-03-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39145
Submission : 2024-02-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26895
Submission : 2013-03-01
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Triheptanoin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Triheptanoin, including repackagers and relabelers. The FDA regulates Triheptanoin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Triheptanoin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Triheptanoin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Triheptanoin supplier is an individual or a company that provides Triheptanoin active pharmaceutical ingredient (API) or Triheptanoin finished formulations upon request. The Triheptanoin suppliers may include Triheptanoin API manufacturers, exporters, distributors and traders.
click here to find a list of Triheptanoin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Triheptanoin DMF (Drug Master File) is a document detailing the whole manufacturing process of Triheptanoin active pharmaceutical ingredient (API) in detail. Different forms of Triheptanoin DMFs exist exist since differing nations have different regulations, such as Triheptanoin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Triheptanoin DMF submitted to regulatory agencies in the US is known as a USDMF. Triheptanoin USDMF includes data on Triheptanoin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Triheptanoin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Triheptanoin suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Triheptanoin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Triheptanoin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Triheptanoin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Triheptanoin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Triheptanoin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Triheptanoin suppliers with NDC on PharmaCompass.
Triheptanoin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Triheptanoin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Triheptanoin GMP manufacturer or Triheptanoin GMP API supplier for your needs.
A Triheptanoin CoA (Certificate of Analysis) is a formal document that attests to Triheptanoin's compliance with Triheptanoin specifications and serves as a tool for batch-level quality control.
Triheptanoin CoA mostly includes findings from lab analyses of a specific batch. For each Triheptanoin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Triheptanoin may be tested according to a variety of international standards, such as European Pharmacopoeia (Triheptanoin EP), Triheptanoin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Triheptanoin USP).
LOOKING FOR A SUPPLIER?